L-T Jia1, Y-C Zhang2, J Li2, Y Tian2, J-F Li2. 1. Department of Clinical Laboratory, The Third Affiliated Hospital of Zhengzhou University, Kangfuqian Street 7, Zhengzhou, 450052, People's Republic of China. litingjia3509@163.com. 2. Department of Clinical Laboratory, The Third Affiliated Hospital of Zhengzhou University, Kangfuqian Street 7, Zhengzhou, 450052, People's Republic of China.
Abstract
PURPOSE: Epithelial ovarian cancer is one of the most lethal female genital tract cancers. Early diagnosis of EOC would benefit the patients a lot. Human epididymis protein 4 (HE4) has been regarded as a new powerful biomarker in diagnosis of EOC; we hope to obtain system knowledge of HE4 and understand the role of HE4 in diagnosis of epithelial ovarian cancer (EOC). METHODS: We searched Pubmed, Embase, Medline, and Chinese National Knowledge Infrastructure (CNKI) for articles that included HE4's origin, characteristics, detection methods, clinical efficacy alone or combined with CA125, the risk of malignancy index, and the risk of ovarian malignancy algorithm. The diagnostic performance for the EOC and the role in the recurrence and procession in EOC were also discussed. RESULTS: We got 83 most related articles and found that there were significantly difference existing among the studies, such as the clinical characteristics of patients, the methodology for measuring HE4, the different cut-offs for HE4 and so on. CONCLUSION: HE4 is a promising biomarker for the early diagnosis of EOC. However, each lab should establish its own reference internal of HE4.
PURPOSE:Epithelial ovarian cancer is one of the most lethal female genital tract cancers. Early diagnosis of EOC would benefit the patients a lot. Humanepididymis protein 4 (HE4) has been regarded as a new powerful biomarker in diagnosis of EOC; we hope to obtain system knowledge of HE4 and understand the role of HE4 in diagnosis of epithelial ovarian cancer (EOC). METHODS: We searched Pubmed, Embase, Medline, and Chinese National Knowledge Infrastructure (CNKI) for articles that included HE4's origin, characteristics, detection methods, clinical efficacy alone or combined with CA125, the risk of malignancy index, and the risk of ovarian malignancy algorithm. The diagnostic performance for the EOC and the role in the recurrence and procession in EOC were also discussed. RESULTS: We got 83 most related articles and found that there were significantly difference existing among the studies, such as the clinical characteristics of patients, the methodology for measuring HE4, the different cut-offs for HE4 and so on. CONCLUSION:HE4 is a promising biomarker for the early diagnosis of EOC. However, each lab should establish its own reference internal of HE4.
Entities:
Keywords:
CA125; Epithelial ovarian cancer; Human epididymis protein 4; The risk of malignancy index; The risk of ovarian malignancy algorithm
Authors: Xiaohong Chang; Xue Ye; Li Dong; Hongyan Cheng; Yexia Cheng; Lirong Zhu; Qinping Liao; Yang Zhao; Li Tian; Tianyun Fu; Jun Chen; Heng Cui Journal: Int J Gynecol Cancer Date: 2011-07 Impact factor: 3.437
Authors: Elena Ioana Braicu; Radoslav Chekerov; Rolf Richter; Carmen Pop; Mani Nassir; Hanna Loefgren; Florin Stamatian; Mustafa Zelal Muallem; Christina Hall; Christina Fotopoulou; Jalid Sehouli; Klaus Pietzner Journal: Ann Surg Oncol Date: 2013-11-12 Impact factor: 5.344
Authors: Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates Journal: Gynecol Oncol Date: 2008-10-12 Impact factor: 5.482
Authors: T Van Gorp; I Cadron; E Despierre; A Daemen; K Leunen; F Amant; D Timmerman; B De Moor; I Vergote Journal: Br J Cancer Date: 2011-02-08 Impact factor: 7.640
Authors: Felix Leung; Marcus Q Bernardini; Marshall D Brown; Yingye Zheng; Rafael Molina; Robert C Bast; Gerard Davis; Stefano Serra; Eleftherios P Diamandis; Vathany Kulasingam Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-07-22 Impact factor: 4.254